MFMatrix Man Him Fung

Matrix Man Him Fung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matrix Man Him Fung has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Opportunistic computed tomography to identify osteoporosis in primary hyperparathyroidism using sestamibi SPECT/CT scans

    by Gary Ka Wai Chan, Xi Xiong, Yan Ho Hui, Matrix Man Him Fung, David T W Lui

    Context: Osteoporosis is a well-recognized complication of primary hyperparathyroidism (PHPT). Objective: We aimed to develop an osteoporosis prediction model for PHPT patients using opportunistic computed tomography (CT)-derived Hounsfield unit (HU) measurements from sestamibi SPECT/CT. Methods: Sestamibi SPECT/CT images from 81 PHPT patients (60 with and 21 without osteoporosis diagnosed by dual-energy x-ray absorptiometry) were analyzed retrospectively. HUs of vertebral bodies were measured. Receiver operating characteristic (ROC) analysis was performed to determine the optimal HU cutoff for each vertebra in predicting osteoporosis. Multivariable logistic regression was used to identify independent clinical parameters associated with osteoporosis. A prediction model based on clinical parameters alone was built. Another prediction model was constructed by further incorporating the HU of the vertebra. Model performance improvement was assessed. Results: Age and body mass index (BMI) were independent risk factors for osteoporosis. The clinical prediction model (age and BMI) achieved an area under the receiver operating characteristic curve (AUROC) of 0.874. Incorporation of HU of T4 vertebra into the clinical model showed the best performance with AUROC of 0.966, sensitivity of 98.2%, and specificity of 85.7%, representing a significant improvement in prediction with change in C-statistics of 0.092 (95% CI, 0.021-0.163; P = .011), net reclassification index of 0.346 (0.041-0.650; P = .026), and incremental discrimination index of 0.329 (0.116-0.542; P = .003). After bootstrap internal validation, the optimism-corrected AUROC was 0.949 (0.882-1.000). Conclusion: Our study demonstrated the feasibility of integrating vertebral HU measurements from sestamibi SPECT/CT into a clinical prediction model for accurately identifying osteoporosis in PHPT patients, offering a potential tool for efficient bone health management and prioritizing timely surgical interventions.

  • The role of artificial intelligence in surgeon-performed ultrasonographic evaluation of cytologically indeterminate thyroid nodules

    by Man Him Matrix Fung, Wai In Ng, Henry Ethan Lee, Tin Ho Chan, Steven Tsz King Leung, Yan Luk, Brian Hung Hin Lang


  • Comparing the Health‐Related Quality of Life at Two Years After Successful Treatment of Relapsed Graves' Disease With Radiofrequency Ablation, Surgery, or Radioiodine

    by Man Him Matrix Fung, Xiaodong Liu, David Tak Wai Lui, Yan Luk, Carlos King Ho Wong, Brian Hung Hin Lang

    Objectives: Conventional definitive treatments of relapsed Graves' disease (GD) include surgery and radioiodine therapy (RAI). Recently, radiofrequency ablation (RFA) has emerged as a potential novel treatment option. This study compared the health‐related quality of life (HRQOL) at 2 years after treatment of relapsed GD with RFA, surgery, and RAI. Methods: Patients with persistent/relapsed GD who underwent RFA, surgery (total thyroidectomy), or RAI at the same tertiary endocrine surgery unit from 2020 to 2022 were recruited to complete the disease‐specific (ThyPRO‐39) and generic (SF‐12V2, SF‐6D and EQ‐5D‐5L) HRQOL questionnaires at two years after each of the above respective treatments. Composite and domain specific scores were compared after propensity score matching for baseline age, sex, thyroid function, and comorbidities. Patients with moderate to severe Graves ophthalmopathy were excluded. Results: Eighty‐five patients completed the questionnaires. In the matched cohort, 45 patients (RFA: 15, Surgery: 15, RAI: 15) were analyzed. Their median age was 34 (30 – 44), and majority were female patients (91%). For the thyroid disease‐specific ThyPRO‐39 questionnaire, the RFA group had significantly lower (better) scores for depressive symptoms than the RAI and surgery groups ( p = 0.046 and 0.009, respectively). The RFA group also had lower (better) scores for anxiety symptoms, hypothyroid symptoms, tiredness, overall quality of life impact scale, and composite scale, albeit differences being not statistically significant. In generic questionnaires, comparable composite scores were observed. These include the physical component score and mental component score in SF‐12v2, the SF‐6D utility score, EQ‐5D‐5L utility score, and EQ‐VAS score. Sensitivity analysis with inverse probability of treatment weighting yielded consistent results. Conclusion: At 2 years after treatment of relapsed GD, single‐session RFA achieved significantly better outcomes in terms of less depressive symptoms and at least comparable outcomes in most HRQOL domains when compared to surgery and RAI, when a disease‐specific questionnaire (ThyPRO‐39) was used. Comparable outcomes from generic HRQOL questionnaires were noted across RFA, surgery, and RAI.


  • High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis

    by Man Him Matrix Fung, Ching Tang, Gin Wai Kwok, Tin Ho Chan, Yan Luk, David Tak Wai Lui, Carlos King Ho Wong, Brian Hung Hin Lang

    Objectives: Cytologically indeterminate thyroid nodules (Bethesda class III or IV) carry a 10–40% risk of malignancy. Diagnostic lobectomies are frequently performed but negative surgeries incur unnecessary costs on the healthcare system, potential complications, and negative impacts on quality of life. Molecular tests (MTs) have been developed to reduce unnecessary surgeries. However, well-validated, high-performance MTs are often expensive, and their cost-effectiveness has not been studied in the Asian population. This study evaluates the rate of unnecessary surgery in the setting without MT (our current practice) and the cost-effectiveness of introducing a commercially available MT for the management of cytologically indeterminate thyroid nodules in a modernized city in Asia. Methods: Management decisions and outcomes of consecutive Bethesda III or IV thyroid nodules in a tertiary endocrine surgery center in Hong Kong were evaluated. Costs of health service provided by the public health system, which covers >90% of healthcare service in the city, were retrieved. A decision tree model was developed to compare the cost-effectiveness in avoiding unnecessary surgeries of current practice versus routine MT from a public healthcare provider’s perspective. In our current practice, MT was not available, and patients with indeterminate nodules received either upfront lobectomy, repeat fine needle aspiration cytology (FNAC), or active surveillance. Results: Over a 4-year period, 2157 FNACs were performed. After exclusion, 1957 FNACs were analyzed, and 18.6% were Bethesda III or IV. Thirty-six percent of these cytologically indeterminate nodules received upfront surgery, with 28% having malignancy in final pathology, that is, 72% of surgeries were unnecessary. Routine MT could reduce 82 unnecessary surgeries/year, 26% more than current practice. Routine MT resulted in an incremental cost-effectiveness ratio of Hong Kong dollar (HKD) 49,102 (US dollar [USD] 6314) per unnecessary surgery. Sensitivity analysis showed test cost of MT contributed significantly to incremental cost-effectiveness ratio. Lowering the commercial price of MT to below HKD 8044 (USD 1031) would render routine MT cost-saving. Conclusion: Currently, a high rate of unnecessary surgeries is being performed for cytologically indeterminate thyroid nodules. MT was more effective in reducing unnecessary surgeries than current practice, but at a higher cost. MT will become cost-saving if the test cost could be lowered.


  • The Two-Year Results of Using Radiofrequency Ablation as a Novel Treatment for Persistent or Relapsed Graves’ Disease: A Prospective Study

    by Man Him Matrix Fung, Yan Luk, Karen K.W. Yuen, Brian Hung Hin Lang

    Objectives Graves' disease(GD) is the most common cause of hyperthyroidism. Antithyroid drug(ATD) is the first-line treatment but when discontinued, >50% of patients suffer relapses. Conventional definitive treatment options include surgery and radioiodine therapy(RAI), each with its own disadvantages. Radiofrequency ablation (RFA) achieved promising short-term remission rates in a previous pilot study. The current study reports our experience of using RFA to treat relapsed GD from the largest cohort of patients with longer period of follow-up. Methods This single-arm prospective study recruited consecutive patients aged ≥18 with persistent / relapsed GD requiring ATD from two tertiary endocrine surgery centers. Those with compressive goiter, suspected thyroid malignancy, moderate to severe Graves' ophthalmopathy, preferred surgery/RAI or pregnant were excluded. Eligible patients received ultrasound-guided RFA to the entire bulk of the thyroid gland. ATDs were discontinued afterwards and thyroid function tests were monitored bi-monthly. The primary outcome was disease remission rate at 24-months follow-up after single-session RFA, defined as being biochemically euthyroid or hypothyroid without ATD. Secondary outcomes were complication rates. Results Of the 100 patients considered, 30 (30.0%) patients were eligible and received RFA. Most were female patients (93.3%). The median total thyroid volume was 23mL (15.9 - 34.5). All completed 24-months follow-up. After single-session RFA, disease remission rates were 60.0% at 12-months and 56.7% at 24-months. Amongst the 13 patients with relapse after RFA, 9 (69%) required lower ATD dose than before RFA; 2 received surgery without complications. Total thyroid volume was the only significant factor associated with relapse after RFA (OR 1.054, 95% CI 1.012 - 1.099, p=0.012). At 24-months, RFA led to disease remission in 100% of the 9 patients with total thyroid volume <20ml, and 35% of patients with total thyroid volume ≥20ml (p=0.007). There was no vocal cord palsy, skin burn, hematoma, or thyroid storm after RFA. Conclusions In a highly selected group of patients with relapsed GD and predominantly small thyroid glands, single-session RFA may achieve disease remission. Smaller total thyroid volume may be a favorable factor associated with disease remission after RFA. The results of this study need to be confirmed with a long-term clinical trial.